869357-62-0

Basic information

• Product Name: methyl 2-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate
• Synonyms: methyl 2-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 869357-62-0
• Molecular Weight: 369.19
• Mol File: 869357-62-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate(869357-62-0)
• EPA Substance Registry System: methyl 2-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate(869357-62-0)

Safety Data

• Hazardous Substances Data: 869357-62-0(Hazardous Substances Data)

Upstream product

• 869357-64-2 methyl 2-chloro-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 367-24-8 4-bromo-2-fluoroaniline 

Downstream Products

• 869357-66-4 2-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridine-3-carboxamide 

Relevant articles and documents

Azacyclo compound serving as protein kinase inhibitor and preparation method of azacyclo compound

The invention relates to an azacyclo compound serving as a protein kinase inhibitor and a preparation method of the azacyclo compound, namely a compound shown as a formula (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, and in the formula, R1, R2, R3, R4 and X are as defined in the specification. The compound is a protein kinase inhibitor, particularly a protein kinase inhibitor Mek inhibitor, and is useful in the treatment of cancer and inflammation in mammals. The invention also discloses a preparation method of the compound as shown in the formula (I) and a pharmaceutical composition containing the compound.

Heterocyclic inhibitors of MEK and methods of use thereof

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.